Long-term Improvement in Clinical Outcomes in Alemtuzumab-Treated RRMS Patients Who Relapsed Between Courses 1 and 2 (CARE-MS I)

No Thumbnail Available
File version
Author(s)
Broadley, S
Wiendl, H
Fernandez, O
Freedman, MS
Izquierdo, G
Lycke, J
Pozzilli, C
Sharrack, B
Singer, BA
Steingo, B
Vermersch, P
Wray, S
Wijmeersch, BV
Ziemssen, T
et al.
Griffith University Author(s)
Primary Supervisor
Other Supervisors
Editor(s)
Date
2018
Size
File type(s)
Location
License
Abstract

Background: In CARE-MS I (NCT00530348), 2 courses of alemtuzumab (baseline: 5 days; 12 months later: 3 days) improved outcomes vs SC IFNB-1a over 2 years in treatment-naive RRMS patients. Durable 6-year efficacy was demonstrated in an extension (NCT00930553) in absence of continuous treatment.

Objective: Evaluate alemtuzumab efficacy over 6 years in CARE-MS I patients who relapsed between Courses 1 and 2.

Methods: Assessments: annualised relapse rate (ARR); 6-month confirmed disability worsening (CDW); 6-month confirmed disability improvement (CDI); MRI disease activity (Gd+ and new/enlarging T2 lesions); new T1 hypointense lesions; brain volume loss (BVL).

Results: 15% of alemtuzumab-treated patients relapsed between Courses 1 and 2. Of these, 93% enrolled in extension; 87% remained through Year 6. ARR in Year 1 (1.3) declined in the year after Course 2 (0.3) and remained low over Years 3–6 (0.3–0.5). At Year 6, 60% were CDW-free, 24% achieved CDI, and most were free of Gd+ (84%) and new/enlarging T2 (71%) lesions, MRI disease activity (69%), and new T1 hypointense lesions (90%). Median percent yearly BVL declined (Years 1–6: –0.67%, –0.17%, –0.20%, –0.11%, –0.21%, –0.24%). After Course 2, 48% of patients received no additional treatment (alemtuzumab or other disease-modifying therapy).

Conclusions: Among 15% of patients who relapsed between alemtuzumab Courses 1 and 2, long-term outcomes were favourable, with nearly one-quarter achieving CDI. These data indicate that relapse after Course 1 is not indicative of subsequent limited treatment response and support administering alemtuzumab according to the approved 2 courses to achieve optimal clinical benefit.

Journal Title
Conference Title
Multiple Sclerosis Journal
Book Title
Edition
Volume
Issue
Thesis Type
Degree Program
School
DOI
Patent number
Funder(s)
Grant identifier(s)
Rights Statement
Rights Statement
Item Access Status
Note
Access the data
Related item(s)
Subject
Clinical sciences
Neurosciences
Science & Technology
Life Sciences & Biomedicine
Clinical Neurology
Neurology
Persistent link to this record
Citation
Broadley, S; Wiendl, H; Fernandez, O; Freedman, MS; Izquierdo, G; Lycke, J; Pozzilli, C; Sharrack, B; Singer, BA; Steingo, B; Vermersch, P; Wray, S; Wijmeersch, BV; Ziemssen, T; et al., Long-term Improvement in Clinical Outcomes in Alemtuzumab-Treated RRMS Patients Who Relapsed Between Courses 1 and 2 (CARE-MS I), Multiple Sclerosis Journal, 2018, 24 (3), pp. 399-399